Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.

Autor: Al-Sawaf O; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Robrecht S; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Zhang C; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Olivieri S; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Chang YM; F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada., Fink AM; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Tausch E; Division of CLL, Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany., Schneider C; Division of CLL, Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany., Ritgen M; Universitätsklinikum Schleswig Holstein, Kiel, Germany., Kreuzer KA; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Sivchev L; Multiprofile Hospital for Active Treatment Pazardjik, Pazardzhik, Bulgaria., Niemann CU; Rigshospitalet, Copenhagen, Denmark., Schwarer A; Box Hill Hospital, Box Hill, VIC, Australia., Loscertales J; Hospital De La Princesa, Madrid, Spain., Weinkove R; Te Rerenga Ora Wellington Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital, Wellington, New Zealand.; Cancer Immunotherapy Program, Malaghan Institute of Medical Research, Wellington, New Zealand., Strumberg D; Evangelisches Krankenhaus Herne, Herne, Germany., Kilfoyle A; Palmerston North Hospital, Palmerston North, New Zealand., Manzoor BS; AbbVie Inc, Chicago, IL., Jawaid D; AbbVie Inc, Chicago, IL., Emechebe N; AbbVie Inc, Chicago, IL., Devine J; Genentech Inc, South San Francisco, CA., Boyer M; F. Hoffmann-La Roche Ltd, Welwyn, United Kingdom., Runkel ED; AbbVie Inc, Chicago, IL., Eichhorst B; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Stilgenbauer S; Division of CLL, Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany., Jiang Y; Genentech Inc, South San Francisco, CA., Hallek M; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Fischer K; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.

Publikováno v: Blood [Blood] 2024 Oct 31; Vol. 144 (18), pp. 1924-1935.

Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany.

Autor: Lux MP; Kooperatives Brustzentrum Paderborn, Paderborn, Germany.; St. Josefs-Krankenhaus, Salzkotten, Germany.; Frauen- und Kinderklinik St. Louise, Paderborn, Germany., Decker T; Onkologie Ravensburg, Ravensburg, Germany., Runkel ED; Pfizer Pharma GmbH, Berlin, Germany., Niyazov A; Pfizer Inc., New York, New York, USA., Quek RGW; Pfizer Inc., San Francisco, California, USA., Marschner N; iOMEDICO AG, Freiburg, Germany., Harbeck N; Brustzentrum, Frauenklinik und CCCLMU, LMU Klinikum, Universität München (LMU), Munich, Germany.

Publikováno v: Breast care (Basel, Switzerland) [Breast Care (Basel)] 2022 Feb; Vol. 17 (1), pp. 40-46. Date of Electronic Publication: 2021 Feb 18.

Mitochondrial stress: balancing friend and foe.

Autor: Runkel ED; Faculty of Biology, Institute of Biology III, Germany; BIOSS Centre for Biological Signalling Studies, Germany; Spemann Graduate School of Biology and Medicine, Germany., Baumeister R; Faculty of Biology, Institute of Biology III, Germany; Faculty of Medicine, ZBMZ Center of Biochemistry and Molecular Cell Research, Germany; BIOSS Centre for Biological Signalling Studies, Germany; Spemann Graduate School of Biology and Medicine, Germany., Schulze E; Faculty of Biology, Institute of Biology III, Germany; BIOSS Centre for Biological Signalling Studies, Germany. Electronic address: ekkehard.schulze@biologie.uni-freiburg.de.

Publikováno v: Experimental gerontology [Exp Gerontol] 2014 Aug; Vol. 56, pp. 194-201. Date of Electronic Publication: 2014 Mar 03.

Surveillance-activated defenses block the ROS-induced mitochondrial unfolded protein response.

Autor: Runkel ED; Spemann Graduate School of Biology and Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany., Liu S, Baumeister R, Schulze E

Publikováno v: PLoS genetics [PLoS Genet] 2013; Vol. 9 (3), pp. e1003346. Date of Electronic Publication: 2013 Mar 14.